Quick filters:
Open Data
Open Code
Pre-registered
Funding Declared
COI Declared
Open Access
Clear Filters
Routine programmatic data show a positive population-level impact of HIV self-testing: the case of Côte d'Ivoire and im…
Simo Fotso A; Johnson C; Vautier A; Kouamé KB; Diop PM; Silhol R; Maheu-Giroux M; Boily MC; Rouveau N; Doumenc-Aïdara C; Baggaley R; Ehui E; Larmarange J; for the ATLAS team
.
AIDS
(Unknown)
Published: 2022
Gut-dependent inflammation and alterations of the intestinal microbiota in individuals with perinatal HIV exposure and …
Tincati C; Ficara M; Ferrari F; Augello M; Dotta L; Tagliabue C; Diana A; Camelli V; Iughetti L; Badolato R; Cellini M; Marchetti G; on behalf of MIRROR Study Group (MIcRobiota study in pediatRic pOpulation gRoup)
.
AIDS
(Unknown)
Published: 2022
Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtr…
Micán R; de Gea Grela A; Cadiñanos J; de Miguel R; Busca C; Bernardino JI; Valencia E; Montes ML; Montejano R; Moreno V; Pérez Valero I; Serrano L; González-García J; Arribas JR; Martín-Carbonero L.
AIDS
(Unknown)
Published: 2022
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexis…
Sax PE; Andreatta K; Molina JM; Daar ES; Hagins D; Acosta R; D'Antoni ML; Chang S; Martin R; Liu H; Blair C; McNicholl I; Gallant J; Collins SE; Martin H; White KL.
AIDS
(Unknown)
Published: 2022
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral …
Mills A; Richmond GJ; Newman C; Osiyemi O; Cade J; Brinson C; De Vente J; Margolis DA; Sutton KC; Wilches V; Hatch S; Roberts J; McCoig C; Garris C; Vandermeulen K; Spreen WR.
AIDS
(Unknown)
Published: 2022
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
Swindells S; Lutz T; Van Zyl L; Porteiro N; Stoll M; Mitha E; Shon A; Benn P; Huang JO; Harrington CM; Hove K; Ford SL; Talarico CL; Chounta V; Crauwels H; Van Solingen-Ristea R; Vanveggel S; Margolis DA; Smith KY; Vandermeulen K; Spreen WR.
AIDS
(Unknown)
Published: 2022
Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV.
Damas J; Ledergerber B; Nadin I; Tarr PE; Stoeckle M; Kunze U; Hauser C; Gutbrod K; Calmy A; Assal F; Schmid P; Hundsberger T; Di Benedetto C; Rossi S; Hasse B; Schlosser L; Du Pasquier R; Darling KEA; Cavassini M; NAMACO study group.
AIDS
(Unknown)
Published: 2021
HIV-1 viral blips are associated with repeated and increasingly high levels of cell-associated HIV-1 RNA transcriptiona…
Suzuki K; Levert A; Yeung J; Starr M; Cameron J; Williams R; Rismanto N; Stark T; Druery D; Prasad S; Ferrarini C; Hanafi I; McNally LP; Cunningham P; Liu Z; Ishida T; Huang CS; Oswald V; Evans L; Symonds G; Brew BJ; Zaunders J.
AIDS
(Unknown)
Published: 2021
Household wealth and HIV incidence over time, rural Uganda, 1994-2018.
Santelli JS; Chen I; Makumbi F; Wei Y; Nalugoda F; Lutalo T; Spindler E; Grilo SA; Deisher A; Grabowski K; Hoffman S; Kagaayi J; Chang LW; Gray R; Wawer M; Serwadda D.
AIDS
(Unknown)
Published: 2021
Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy…
Granger LA; Huettner I; Debeljak F; Kaleebu P; Schechter M; Tambussi G; Weber J; Miro JM; Phillips R; Babiker A; Cooper DA; Fisher M; Ramjee G; Fidler S; Frater J; Fox J; Doores KJ.
AIDS
(Unknown)
Published: 2021
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a …
Keene CM; Griesel R; Zhao Y; Gcwabe Z; Sayed K; Hill A; Cassidy T; Ngwenya O; Jackson A; van Zyl G; Schutz C; Goliath R; Flowers T; Goemaere E; Wiesner L; Simmons B; Maartens G; Meintjes G.
AIDS
(Unknown)
Published: 2021